Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study

Charles X Kim, Kent R Bailey, George G Klee, Allison A Ellington, Guanghui Liu, Thomas H Mosley Jr, Hamid Rehman, Iftikhar J Kullo, Charles X Kim, Kent R Bailey, George G Klee, Allison A Ellington, Guanghui Liu, Thomas H Mosley Jr, Hamid Rehman, Iftikhar J Kullo

Abstract

Background: Cardiovascular disease (CVD) susceptibility differs between men and women and varies with ethnicity. This variability is not entirely explained by conventional CVD risk factors. We examined differences in circulating levels of 47 novel protein markers of CVD in 2561 men and women of African-American (AA) and non-Hispanic White (NHW) ethnicity, enrolled at geographically distinct sites.

Methodology/principal findings: Participants (1,324 AAs, mean age 63.5 y, 71% women; 1,237 NHWs, mean age 58.9 y, 57% women) belonged to sibships ascertained on the basis of hypertension. Solid-phase immunoassays and immunoturbidometric, clot-based, chromogenic, and electrophoretic assays were used to measure the 47 protein markers in plasma or serum. Marker levels were log transformed and outliers were adjusted to within 4 SD. To identify markers independently associated with sex or ethnicity, we employed multivariable regression analyses that adjusted for conventional risk factors, prior history of CVD, medication use and lifestyle factors (physical activity, alcohol consumption and education). Generalized estimating equations were used to correct for intrafamilial correlations. After adjustment for the above covariates, female sex was associated with higher levels of 29 markers and lower levels of 6 markers. Female sex was independently associated with higher levels of several inflammatory markers as well as lipoproteins, adipokines, natriuretic peptides, vasoconstrictor peptides and markers of calcification and thrombosis. AA ethnicity was associated with higher levels of 19 markers and lower levels of 6 markers, including higher levels of several inflammatory makers, higher leptin and lower adiponectin levels, lower levels of vasodilator-natriuretic peptides, higher levels of vasoconstrictor-antidiuretic peptides and markers of calcification and thrombosis.

Conclusions/significance: Plasma levels of several novel protein markers of CVD differ significantly in the context of sex and ethnicity. These results have implications for individualized CVD risk assessment.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Association of female sex with…
Figure 1. Association of female sex with circulating levels of protein markers.
Multivariable regression analyses; markers independently associated with female sex (graphical representation of Table 4, P<0.05, β±SE for 1 log change in a marker level is shown).
Figure 2. Association of African American ethnicity…
Figure 2. Association of African American ethnicity with circulating levels of protein markers.
Multivariable regression analyses; markers independently associated with African American ethnicity (graphical representation of Table 5, P<0.0, β±SE for 1 log change in a marker level is shown).

References

    1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847.
    1. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92:1752–1759.
    1. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310–315.
    1. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.
    1. (2002) Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function? Heart. 2002;88:222–228.
    1. Greenland P, Smith SC, Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104:1863–1867.
    1. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. Jama. 2004;291:210–215.
    1. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. Jama. 2001;285:2481–2485.
    1. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT. Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis. 2008;199:3–11.
    1. Gerszten RE, Accurso F, Bernard GR, Caprioli RM, Klee EW, et al. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol. 2008;295:L16–22.
    1. Granger CB, Van Eyk JE, Mockrin SC, Anderson NL. National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation. 2004;109:1697–1703.
    1. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241.
    1. Ellington AA, Kullo IJ, Bailey KR, Klee GG. Measurement and Quality Control Issues in Multiplex Protein Assays: A Case Study. Clin Chem Jun. 2009;55:1092–1099.
    1. (2002) Multi-center genetic study of hypertension: The Family Blood Pressure Program (FBPP). Hypertension. 39:3–9.
    1. (1989) The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 129:687–702.
    1. Melton LJ., 3rd History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266–274.
    1. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005;51:1823–1829.
    1. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112–119.
    1. Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem. 2006;52:1144–1151.
    1. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004;50:234–236.
    1. Westgard JO, Barry PL, Hunt MR, Groth T. A multi-rule Shewhart chart for quality control in clinical chemistry. Clin Chem. 1981;27:493–501.
    1. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121–130.
    1. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837–842.
    1. Lowe GD, Sweetnam PM, Yarnell JW, Rumley A, Rumley C, et al. C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol. 2004;24:1957–1962.
    1. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–2116.
    1. Knopp RH, Paramsothy P, Retzlaff BM, Fish B, Walden C, et al. Gender differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. Curr Atheroscler Rep. 2005;7:472–479.
    1. Fan AZ, Dwyer JH. Sex differences in the relation of HDL cholesterol to progression of carotid intima-media thickness: the Los Angeles Atherosclerosis Study. Atherosclerosis. 2007;195:e191–196.
    1. Vaidya D, Dobs A, Gapstur SM, Golden SH, Hankinson A, et al. The association of endogenous sex hormones with lipoprotein subfraction profile in the Multi-Ethnic Study of Atherosclerosis. Metabolism. 2008;57:782–790.
    1. Lieb W, Sullivan LM, Harris TB, Roubenoff R, Benjamin EJ, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease and total mortality in the elderly. Diabetes Care 2008
    1. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab. 2003;88:4848–4856.
    1. Stumvoll M, Haring H. Resistin and adiponectin–of mice and men. Obes Res. 2002;10:1197–1199.
    1. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, et al. Resistin, central obesity, and type 2 diabetes. Lancet. 2002;359:46–47.
    1. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334:1092–1101.
    1. Verma S, Li SH, Wang CH, Fedak PW, Li RK, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003;108:736–740.
    1. Sowers JR. Endocrine functions of adipose tissue: focus on adiponectin. Clin Cornerstone. 2008;9:32–40.
    1. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol. 2007;165:164–174.
    1. Rothenbacher D, Brenner H, Marz W, Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J. 2005;26:1640–1646.
    1. Romero-Corral A, Sierra-Johnson J, Lopez-Jimenez F, Thomas RJ, Singh P, et al. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population. Nat Clin Pract Cardiovasc Med. 2008;5:418–425.
    1. Sladek CD, Somponpun SJ. Estrogen receptors: their roles in regulation of vasopressin release for maintenance of fluid and electrolyte homeostasis. Front Neuroendocrinol. 2008;29:114–127.
    1. Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol. 2007;49:109–116.
    1. Gerbes AL, Dagnino L, Nguyen T, Nemer M. Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. J Clin Endocrinol Metab. 1994;78:1307–1311.
    1. Kuroski de Bold ML. Estrogen, natriuretic peptides and the renin-angiotensin system. Cardiovasc Res. 1999;41:524–531.
    1. Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res. 2004;64:24–31.
    1. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, et al. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int. 2000;11:295–303.
    1. Lukacs JL, Booth S, Kleerekoper M, Ansbacher R, Rock CL, et al. Differential associations for menopause and age in measures of vitamin K, osteocalcin, and bone density: a cross-sectional exploratory study in healthy volunteers. Menopause. 2006;13:799–808.
    1. Sukhu K, Poovalingam V, Mahomed R, Giangrande PL. Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease. Clin Lab Haematol. 2003;25:247–249.
    1. Albert MA, Ridker PM. Inflammatory biomarkers in African Americans: a potential link to accelerated atherosclerosis. Rev Cardiovasc Med. 2004;5(Suppl 3):S22–27.
    1. Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, et al. Sex Differences in Medical Care and Early Death After Acute Myocardial Infarction. Circulation. 2008
    1. Kaplan RC, McGinn AP, Baird AE, Hendrix SL, Kooperberg C, et al. Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study. J Stroke Cerebrovasc Dis. 2008;17:344–355.
    1. Palmas W, Ma S, Jacobs DR, Jr, Arnett D, Jackson S, et al. Ethnicity and sex modify the association of serum c-reactive protein with microalbuminuria. Ethn Dis. 2008;18:324–329.
    1. Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, Matthews KA, Johnston J, et al. Ethnic differences in C-reactive protein concentrations. Clin Chem. 2008;54:1027–1037.
    1. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604.
    1. Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol. 2007;99:1364–1368.
    1. Khawaja FJ, Bailey KR, Turner ST, Kardia SL, Mosley TH, Jr, et al. Association of novel risk factors with the ankle brachial index in African American and non-Hispanic white populations. Mayo Clin Proc. 2007;82:709–716.
    1. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem. 2000;275:25781–25790.
    1. Davis CL, Wang X, Snieder H, Treiber FA. Genetic and environmental determinants of lipid profile in black and white youth: a study of four candidate genes. Ethn Dis. 2005;15:568–577.
    1. Okosun IS, Choi S, Hash R, Dever GE. Apolipoprotein B, ratio of total cholesterol to HDL-C, and blood pressure in abdominally obese white and black American women. J Hum Hypertens. 2001;15:299–305.
    1. Klos KL, Kardia SL, Hixson JE, Turner ST, Hanis C, et al. Linkage analysis of plasma ApoE in three ethnic groups: multiple genes with context-dependent effects. Ann Hum Genet. 2005;69:157–167.
    1. Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics. 2007;17:647–656.
    1. Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis. 2008;199:110–115.
    1. Degawa-Yamauchi M, Dilts JR, Bovenkerk JE, Saha C, Pratt JH, et al. Lower serum adiponectin levels in African-American boys. Obes Res. 2003;11:1384–1390.
    1. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, et al. Adipokines and risk of type 2 diabetes in older men. Diabetes Care. 2007;30:1200–1205.
    1. Considine RV, Premkumar A, Reynolds JC, Sebring NG, Ricks M, et al. Adiponectin and leptin in African Americans. Obesity (Silver Spring) 2008;16:428–434.
    1. Bakris G, Bursztyn M, Gavras I, Bresnahan M, Gavras H. Role of vasopressin in essential hypertension: racial differences. J Hypertens. 1997;15:545–550.
    1. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51:627–633.
    1. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004;44:1970–1976.
    1. Gundberg CM, Looker AC, Nieman SD, Calvo MS. Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity. Bone. 2002;31:703–708.
    1. Leder BZ, Araujo AB, Travison TG, McKinlay JB. Racial and ethnic differences in bone turnover markers in men. J Clin Endocrinol Metab. 2007;92:3453–3457.
    1. Steinvil A, Kordova-Biezuner L, Shapira I, Berliner S, Rogowski O. Short-term exposure to air pollution and inflammation-sensitive biomarkers. Environ Res. 2008;106:51–61.
    1. Hoffmann B, Moebus S, Dragano N, Stang A, Mohlenkamp S, et al. Chronic residential exposure to particulate matter air pollution and systemic inflammatory markers. Environ Health Perspect. 2009;117:1302–1308.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir